作者
Mathias Jachs,Aitor Odriozola,Fanny Turón,Lucile Moga,Luís Téllez,Petra Fischer,Dario Saltini,Wilhelmus J. Kwanten,Maria Grazia Grasso,Elba Llop,Yuly P. Mendoza,Angelo Armandi,Julia Thalhammer,Carlos A. Pardo,Antonio Colecchia,Federico Ravaioli,Benjamin Maasoumy,Wim Laleman,José Presa,Jörn M. Schattenberg,Annalisa Berzigotti,José Luís Calleja,V. Calvaruso,Sven Francque,Filippo Schepis,Bogdan Procopeț,Agustín Albillos,Pierre‐Emmanuel Rautou,Juan Carlos García‐Pagán,Ángela Puente,José Ignacio Fortea,Thomas Reiberger,Mattias Mandorfer
摘要
In patients with compensated advanced chronic liver disease (cACLD), risk of clinically significant portal hypertension (CSPH) can be estimated by applying non-invasive tests such as liver stiffness measurement (LSM), platelet count, and, in some cases, BMI. We aimed to assess the diagnostic utility of spleen stiffness measurement (SSM) at 100 Hz as a standalone non-invasive test for CSPH and to evaluate its incremental value compared with the ANTICIPATE±NASH model in patients with cACLD.